Head-to-head evidence
HRS-5632 vs Kylo-11
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: Lipoprotein(a) · full Atherosclerotic Cardiovascular Disease pipeline
HRS-5632
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06732154 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled study, which is a sound design, but the primary measure is adverse-event and safety monitoring rather than a lipid or cardiovascular outcome, and no results have been posted yet.
Next expected readout: April 2027 · NCT07185776 (registry estimate)
Kylo-11
Developed by Kylonova (Xiamen) Biopharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07327840 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-5632's landscape · Kylo-11's landscape